Ìý
Ìý
Tuberculosis Trials Consortium Clinical Research Services (TBTC)Ìý
Click here for project description
Ìý
Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB
Click here for project description
Ìý
GeneXpert or chest x-rays or tuberculin testing for household contact assessment – a cluster randomized trial
Click here for project description
Ìý
Cost-effectiveness of TB screening in Nunavik
Ìý
Decision tree and supporting materials
Nunavik TB screening manuscript
Nunavik TB screening supplement
Ìý
Enhancing the public health impact of latent TB infection diagnosis and treatment: A pragmatic cluster randomized trial.
ClickÌýhereÌýto access the protocol
ClickÌýhereÌýfor training material
ClickÌýhereÌýfor registry analysis tool
ClickÌýhereÌýfor mTST material
ClickÌýhereÌýfor publications
Click here for questionnaires
Ìý
Ìý
A randomized clinical trial of 4 months Rifampin vs. 9 months Isoniazid for latent TB infection (Phase 3 effectiveness)
&
A randomized trial to compare completion and tolerability of 4 months Rifampin (4 RIF) and 9 months Isoniazid (9 INH) for treatment of latent TB in children
Click here to have more details on the protocolÌý
Click here to have access to the RCT 4v9 children publication
Click here to have access to the RCT 4v9 adult publicationÌýÌý
Ìý
Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Click here to read the study protocol
Meta-analysis of Individual patient Data (IPD) of Patients with Multi-Drug Resistant Tuberculosis. Click here for resources related to this project.
Ìý
Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý
Ìý
Ìý
Ìý
Partnerships
PAHO/WHO Collaborating CentersÌý |
|
Advancing New TB Vaccines for the World |
|
Our vision:ÌýA world where diagnosis guides the way to health for all peopleOur mission:ÌýTurning complex diagnostic challenges into simple solutions to overcome diseases of poverty and transform lives |
|
Manipal Centre for Infectious Disease based at Manipal University,ÌýKarnataka, India |
|
SGC is aÌýpublic-private partnership that supports the discovery of new medicines through open access research.Ìý |
|
TB REACH: FINDING AND TREATING PEOPLE WITH TB IN THE WORLD’S POOREST COMMUNITIESÌý Partnership involvement |
|
TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. |
Ìý